MannKind is trading at $4.18 (+5.03%) as the stock climbs alongside a broader risk-on tone in the biotechnology sector, despite a lack of company-specific news.
- The move appears consistent with sector-wide momentum, as the broader biotech sector has gained 2.08% during the session.
- A general rise in U.S. equities is providing a tailwind for smaller-cap biotech names like MannKind.